Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

In the final analysis, at 120 months of follow-up, median progression-free survival(PFS) was comparable between the treatment groups: 110.6 months with R2 vs 102.8 months with R-Chemo, according to the independent review committee assessment.

在最终分析中，随访120个月后，独立评审委员会评估显示，两组治疗的中位无进展生存期（PFS）相当：R2组为110.6个月，而R-Chemo组为102.8个月。

The 10-year PFS rates were 46.4% for R2 and 46.6% for R-chemo.

10年无进展生存率（PFS）为R2组46.4%，R-chemo组46.6%。

Median overall survival(OS) and time-to-next lymphoma treatment (TTNLT) were not reached in either arm; 10-year OS rates were 82.4% for R2 and 81.1% for R-chemo, and 10-year TTNLT rates were 62.2% for R2 and 66.3% for R-chemo.

两组中位总生存（OS）和下一次淋巴瘤治疗时间（TTNLT）均未达到；10年总生存率R2组为82.4%，R-chemo组为81.1%，10年下一次淋巴瘤治疗时间率R2组为62.2%，R-chemo组为66.3%。

Overall, patients with progression of disease within 24 months (POD24) had a poorer prognosis than those without POD24 (hazard ratio, 6.215; P< .0001); however, no difference was observed between the study groups.

总体而言，24个月内疾病进展（POD24）的患者预后比没有POD24的患者差（风险比，6.215；P< .0001）；然而，在研究组之间未观察到差异。

The incidenceof second primary malignancies (SPMs) was 2.11 cases per 100 patient-years (95% confidence interval, 1.80-2.46).

第二原发恶性肿瘤（SPMs）的发病率为每100患者年2.11例（95%置信区间，1.80-2.46）。

Only 9 transformations occurred after 24 months (3 with R2 vs 6 with R-chemo).

仅在24个月后发生了9例转化（其中3例使用R2治疗，6例使用R化疗）。

In each study group, 87 patients died, mainly because of lymphoma progression and SPMs.

在每个研究组中，有87名患者死亡，主要是由于淋巴瘤进展和第二原发恶性肿瘤（SPMs）。

This long-term follow-up of RELEVANCE confirmed that R2 provides a chemotherapy-free alternative to immunochemotherapy in this patient population.

RELEVANCE的这项长期随访证实，R2为这一患者群体提供了一种无化疗的免疫化疗替代方案。

This trial was registered at www.clinicaltrials.gov as NCT01476787 and NCT01650701 and at EudraCT as 2011-002792-42.

这项试验已在www.clinicaltrials.gov上注册，注册号为NCT01476787和NCT01650701，在EudraCT上的注册号为2011-002792-42。